Anixa biosciences announces submission of protocol amendment for car-t trial

Amendment will allow a second dose of car-t therapy to suitable patients san jose, calif. , sept. 30, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer, today announced that it and partner moffitt cancer center ("moffitt") have submitted an amendment to the current protocol that governs its ongoing clinical trial utilizing a car-t therapy to treat ovarian cancer (nct05316129).
CAR Ratings Summary
CAR Quant Ranking